# OnCo record nct04152499 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04152499/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04152499", "NCT04152499" ;
  schema:name "Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)"@en ;
  schema:description "A phase 1/2 trial of Sacituzumab tirumotecan in ovarian cancer and non-small-cell lung cancer, run by Klus Pharma Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04152499/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04152499> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2020-02-28" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/cervical/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-tirumotecan/> ;
  onco:companies <https://onco.cc/companies/kelun-biotech/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04152499-j-hematol-oncol-2025/> .